USF-LVHN SELECT
PD18-04 SURVIVAL IS DRAMATICALLY IMPROVED FOR MRCC PATIENTS WITH SARCOMATOID FEATURES WHO ARE TREATED WITH CYTOREDUCTIVE NEPHRECTOMY AND IMMUNE CHECKPOINT INHIBITORS REGARDLESS OF TREATMENT SEQUENCE
Publication/Presentation Date
5-2024
Volume
211
Issue
5
First Page
433
Last Page
433
Published In/Presented At
Shapiro, Daniel D.; Karam, Jose A.; Master, Viraj A.; Spiess, Philippe E.; Peyton, Charles C.; Psutka, Sarah P.; Raman, Jay D.; Mercinelli, Chiara; Nicaise, Edouard; Robertson, Nicholas D.; Sirard, R. Barry; Jani, Amber; Necchi, Andrea; Sexton, Wade J.; Manley, Brandon J.; Patil, Dattatraya; Allen, Glenn O.; Matin, Surena F.; Abel, Edwin J.. PD18-04 SURVIVAL IS DRAMATICALLY IMPROVED FOR MRCC PATIENTS WITH SARCOMATOID FEATURES WHO ARE TREATED WITH CYTOREDUCTIVE NEPHRECTOMY AND IMMUNE CHECKPOINT INHIBITORS REGARDLESS OF TREATMENT SEQUENCE. The Journal of Urology 211(5S):p e433, May 2024. | DOI: 10.1097/01.JU.0001008596.32809.c5.04
Disciplines
Medical Education | Medicine and Health Sciences
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article